Patents by Inventor Gera Neufeld

Gera Neufeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED SEMAPHORIN 3A, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF
    Publication number: 20230272020
    Abstract: Provided herein are modified forms of Semaphorin 3A (Sema3A) polypeptide having one or more amino acid substitutions and/or deletions compared to a wild type Sema3A protein. Further provided are nucleic acid molecules encoding the modified Sema3A polypeptide, compositions including the same and uses thereof in treating various immune-related conditions.
    Type: Application
    Filed: June 3, 2021
    Publication date: August 31, 2023
    Inventors: Zahava VADASZ, Elias TOUBI, Nasren EIZA, Adi SABAG, Gera NEUFELD, Ofra KESSLER, E. Yvonne JONES
  • Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases
    Patent number: 10561707
    Abstract: The present invention relates, according to some embodiments, method of treating eye diseases, such as AMD by administering Semaphorin 3C (Sema3C) or a variant thereof having amino acid modifications at furin-like pro-protein convertase cleavage sites, rendering these sites resistant to cleavage.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: February 18, 2020
    Assignees: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., RAMBAM MED-TECH LTD.
    Inventors: Shira Toledano, Ofra Kessler, Gera Neufeld, Yoreh Barak, Yelena Mumblat
  • PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS
    Publication number: 20190040470
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Application
    Filed: January 26, 2018
    Publication date: February 7, 2019
    Inventors: Gera NEUFELD, Gal AKIRI, Zahava VADASZ, Stela GENGRINOVITCH
  • COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF CANCER AND METHODS OF SELECTION THEREOF
    Publication number: 20180055907
    Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
    Type: Application
    Filed: November 5, 2017
    Publication date: March 1, 2018
    Applicant: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
    Inventors: Gera NEUFELD, Boaz Kigel, Ofra Kessler, Asya Varshavsky
  • Semaphorin 3C variants, compositions comprising said variants and methods of use thereof
    Patent number: 9896490
    Abstract: The present invention relates, according to some embodiments, to variants of Semaphorin 3C (Sema3C) having amino acid modifications at furin-like pro-protein convertase cleavage sites, rendering these sites resistant to cleavage. The invention further provides, according to certain embodiments, compositions comprising the Sema3C variants, and methods of using the compositions for suppressing the growth of tumors and/or inhibiting the development of tumor metastases.
    Type: Grant
    Filed: September 7, 2014
    Date of Patent: February 20, 2018
    Assignee: RAPPAPORT FAMILY NSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
    Inventors: Gera Neufeld, Yelena Mumblat, Ofra Kessler
  • Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof
    Patent number: 9808506
    Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: November 7, 2017
    Assignee: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
    Inventors: Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
  • SEMAPHORIN 3C VARIANTS, COMPOSITIONS COMPRISING SAID VARIANTS AND METHODS OF USE THEREOF IN TREATING EYE DISEASES
    Publication number: 20170173111
    Abstract: The present invention relates, according to some embodiments, method of treating eye diseases, such as AMD by administering Semaphorin 3C (Sema3C) or a variant thereof having amino acid modifications at furin-like pro-protein convertase cleavage sites, rendering these sites resistant to cleavage.
    Type: Application
    Filed: January 24, 2017
    Publication date: June 22, 2017
    Inventors: Shira TOLEDANO, Ofra Kessler, Gera Neufeld, Yoreh Barak, Yelena Mumblat
  • Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
    Patent number: 9617347
    Abstract: The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: April 11, 2017
    Assignee: Technion Research & Development Foundation Limited
    Inventor: Gera Neufeld
  • SEMAPHORIN 3C VARIANTS, COMPOSITIONS COMPRISING SAID VARIANTS AND METHODS OF USE THEREOF
    Publication number: 20160311873
    Abstract: The present invention relates, according to some embodiments, to variants of Semaphorin 3C (Sema3C) having amino acid modifications at furin-like pro-protein convertase cleavage sites, rendering these sites resistant to cleavage. The invention further provides, according to certain embodiments, compositions comprising the Sema3C variants, and methods of using the compositions for suppressing the growth of tumors and/or inhibiting the development of tumor metastases.
    Type: Application
    Filed: September 7, 2014
    Publication date: October 27, 2016
    Inventors: Gera NEUFELD, Yelena MUMBLAT, Ofra KESSLER
  • COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF CANCER AND METHODS OF SELECTION THEREOF
    Publication number: 20160263182
    Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
    Type: Application
    Filed: September 8, 2015
    Publication date: September 15, 2016
    Inventors: Gera NEUFELD, Boaz Kigel, Ofra Kessler, Asya Varshavsky
  • COMPOSITIONS AND METHODS FOR TREATING TUMORS, FIBROSIS, AND PULMONARY ALVEOLAR PROTEINOSIS
    Publication number: 20160222128
    Abstract: The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.
    Type: Application
    Filed: February 8, 2016
    Publication date: August 4, 2016
    Applicant: Technion Research & Development Foundation Limited
    Inventor: Gera NEUFELD
  • Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
    Patent number: 9255271
    Abstract: The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: February 9, 2016
    Assignee: Technion Research & Development Foundation Ltd
    Inventor: Gera Neufeld
  • Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
    Patent number: 9155781
    Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: October 13, 2015
    Assignee: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
    Inventors: Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
  • COMPOSITIONS AND METHODS FOR TREATING TUMORS, FIBROSIS, AND PULMONARY ALVEOLAR PROTEINOSIS
    Publication number: 20150044199
    Abstract: The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.
    Type: Application
    Filed: July 15, 2014
    Publication date: February 12, 2015
    Inventor: Gera NEUFELD
  • PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS
    Publication number: 20140302499
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventors: Gera NEUFELD, Gal AKIRI, Zahava VADASZ, Stela GENGRINOVITCH
  • Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors
    Patent number: 8815823
    Abstract: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: August 26, 2014
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Gera Neufeld, Gal Akiri, Zahava Vadasz, Stela Gengrinovitch
  • Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
    Patent number: 8815824
    Abstract: The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 26, 2014
    Assignee: Technion Research & Development Foundation Ltd.
    Inventor: Gera Neufeld
  • HIGH AFFINITY MOLECULES CAPABLE OF BINDING A TYPE A PLEXIN RECEPTOR AND USES OF SAME
    Publication number: 20130330349
    Abstract: A high affinity molecule is provided. The high affinity molecule comprises a binding domain which binds a type-A plexin receptor, wherein said binding domain inhibits proliferative signals through said type-A plexin receptor but does not interfere with binding of a neuropilin or semaphorin 6A to said type-A plexin receptor.
    Type: Application
    Filed: February 23, 2012
    Publication date: December 12, 2013
    Applicant: Rappaport Family Institute for Research in the Medical Sciences
    Inventors: Gera Neufeld, Boaz Kigel, Noa Rabinowicz, Asya Varshavsky, Ofra Kessler
  • COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF
    Publication number: 20130287726
    Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
    Type: Application
    Filed: July 15, 2013
    Publication date: October 31, 2013
    Inventors: Gera NEUFELD, Boaz Kigel, Ofra Kessler, Asya Varshavsky
  • Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
    Patent number: 8513194
    Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: August 20, 2013
    Assignee: Rappaport Family Institute for Research in the Medical Sciences
    Inventors: Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky